- Juva Life Inc. (JUVA) advances its JUVA-019 from discovery into pre-clinical development
- JUVA-019 is a small, non-cannabinoid molecule which has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation
- Additional studies confirm that JUVA-019 does not require cannabinoids to elicit the observed anti-inflammatory effects
- The company’s next steps will follow the prescriptive advancement of JUVA-019 through standard pre-clinical and non-clinical drug development processes
- Juva Life Inc. (JUVA) is up by 13.46 per cent trading at $0.30 per share as of 2:31 p.m. EST
Juva Life Inc. (JUVA) has advanced its JUVA-019 from discovery into pre-clinical development.
JUVA-019 is a small, non-cannabinoid molecule that has demonstrated potent anti-inflammatory properties in phenotypic assays of inflammation.
Laboratory studies are completed verifying these initial findings.
The studies suggest that JUVA-019 is a potent stand-alone compound with anti-inflammatory activity that is not dependent on synergism with known cannabinoids.
Doug Chloupek, Juva founder and CEO, stated,
“This is an important advancement in the validation of our platform, in that it suggests that there are unappreciated non-cannabinoid molecules in cannabis that may be both clinically and commercially valuable.”
Researchers at Juva conducted multiple studies, including a comparative study that explored multiple modes of action for JUVA-019.
The goal of this study was to evaluate the inhibition of IL1-beta and IFNg biomarkers when introduced to JUVA-019 as a stand-alone molecule.
Additional studies confirm that JUVA-019 does not require cannabinoids to elicit the observed anti-inflammatory effects.
The company’s next steps will follow the prescriptive advancement of JUVA-019 through standard pre-clinical and non-clinical drug development processes.
It will begin by focusing on exploring the structural requirements for activity.
PD/PK relationships in a battery of in vivo models of human disease will also be explored.
Juva’s focus is the development of safe and effective treatments targeting the global anti-inflammatory therapeutics market.
Juva Life Inc. (JUVA) is up by 13.46 per cent trading at $0.30 per share as of 2:31 p.m. EST.